Article

System augments LASIK outcomes for mixed astigmatism

Chicago—Wavefront-guided CustomCornea LASIK using the LADARVision 4000 Excimer Laser System (Alcon Laboratories) safely and effectively treats mixed astigmatism and with some advantages compared with conventional LASIK, said James J. Salz, MD, at the refractive surgery subspecialty day meeting sponsored by the International Society of Refractive Surgery of the American Academy of Ophthalmology.

Speaking on behalf of the CustomCornea Study Group, Dr. Salz presented the 6-month results from 110 eyes treated with the wavefront-guided LASIK procedure. In addition, he reported findings from a comparative substudy between 83 eyes treated with CustomCornea LASIK and a control group of 26 eyes having a similar preoperative refractive range that were treated under the same protocol with conventional LASIK.

The uncorrected visual acuity (UCVA) and refractive outcomes were excellent for CustomCornea treatment, and the results were similar when comparing the overall and substudy CustomCornea populations. The substudy further supported CustomCornea treatment in evaluation of high-contrast and low-contrast best spectacle-corrected visual acuity (BSCVA) gain versus loss and higher-order aberrations from preoperative.

All treatments were performed using the LADARVision 4000 System over a 6.5-mm optical zone with a 1.25-mm peripheral blend zone. Conventional LASIK was based on cycloplegic refraction. CustomCornea LASIK was based on measurements of up to sixth-order higher-order aberrations using Alcon's LADARWave aberrometer. Wavefronts were measured in the dilated eye to ensure capture of aberrations occurring in the periphery (e.g., spherical aberration) that would otherwise not be fully measurable in the undilated eye. Laser ablation was applied onto the exact corneal position that is matched to the wavefront measurement. For an individual eye, the center of laser ablation corresponds to the center of the undilated pupil with registration to fixed limbal and reticle references that were maintained throughout the ablation.

At 6 months, 100% of the enrolled eyes were available. For the overall CustomCornea cohort, UCVA was 20/20 or better in 64% of eyes while 87% had 20/25 or better and 98% had 20/40 or better UCVA. Considering the CustomCornea subgroup of 94 eyes with preoperative BSCVA of 20/20 or better, 71% achieved UCVA of 20/20 or better.

In the substudy, again considering eyes with preoperative BSCVA of 20/20 or better, UCVA of 20/20 or better was achieved by 73% of eyes treated with CustomCornea LASIK compared with 65% of those treated with conventional LASIK.

For accuracy of MRSE, 76% of eyes for the overall CustomCornea cohort were within 0.5 D of emmetropia and 91% were within 1 D of emmetropia. For the substudy, 81% of eyes undergoing CustomCornea LASIK were within 0.5 D of emmetropia compared with only 65% of those undergoing conventional LASIK. Vector analysis showed the two techniques offered similar effectiveness in astigmatism treatment that averaged about 90% correction of manifest cylinder for the overall CustomCornea cohort and both substudy populations.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times)  ASCRS 2025: Joaquin De Rojas, MD, leverages machine learning model to predict arcuate outcomes
(Image credit: Ophthalmology Times) ASCRS 2025: AnnMarie Hipsley, DPT, PhD, presents VESA for biomechanical simulation of presbyopia progression
Shehzad Batliwala, DO, aka Dr. Shehz, discussed humanitarian ophthalmology and performing refractive surgery in low-resource, high-risk areas at the ASCRS Foundation Symposium.
(Image credit: Ophthalmology Times) ASCRS 2025: Advancing vitreous care with Inder Paul Singh, MD
(Image credit: Ophthalmology Times) The Residency Report: Study provides new insights into USH2A target end points
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
© 2025 MJH Life Sciences

All rights reserved.